<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861938</url>
  </required_header>
  <id_info>
    <org_study_id>0419-12-HMO</org_study_id>
    <nct_id>NCT01861938</nct_id>
  </id_info>
  <brief_title>Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients</brief_title>
  <official_title>Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is based on the hypothesis that stimulation of the immune response against the&#xD;
      tumor can help destroy residual tumor in melanoma patients with very high risk for disease&#xD;
      recurrence and in patients with relatively low tumor burden who already got first line&#xD;
      treatment for their disease.&#xD;
&#xD;
      Ongoing clinical trials in the Hadassah Hospital have shown that vaccination of patients with&#xD;
      a cell line of tumor cells from the patient himself, or with a combination of three cell&#xD;
      lines that partially match the patient's cell characteristics, could improve the immune&#xD;
      response against the tumor, was associated with improved disease-free and overall survival.&#xD;
&#xD;
      In this study, the investigators will evaluate the efficacy of a modified tumor cell vaccine,&#xD;
      in terms of immune response,improved disease-free and overall survival. The vaccine consists&#xD;
      of a cell line that has a high expression level of melanoma molecules, and has been&#xD;
      genetically modified to induce a strong immune response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse effects</measure>
    <time_frame>For 20 weeks from the start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall and disease free survival</measure>
    <time_frame>For at least five years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Emergence of anti-tumor T cell reactivity</measure>
    <time_frame>To be measured one month after the last vaccine was admininstered, on average 18-20 weeks after treatment start</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>High Risk HLA-A2+ Melanoma</condition>
  <condition>Metastatic Disease</condition>
  <arm_group>
    <arm_group_label>Melanoma vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Melanoma vaccine modified to express HLA A2/4-1BB ligand</intervention_name>
    <arm_group_label>Melanoma vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients included in this protocol must carry one or more of the following tissue&#xD;
             typing alleles: HLA-A2, -A24, -A33, -B35, -B49, -CW04/12(04/08). We estimate that 50%&#xD;
             of melanoma patients will be eligible.&#xD;
&#xD;
          2. Cutaneous malignant melanoma AJCC stage IIb (over 4 mm) or IIc (ulcerated melanoma&#xD;
             over 4mm).&#xD;
&#xD;
          3. Metastatic melanoma AJCC stage III (nodal involvement, N1-3a,b) post surgical removal&#xD;
             of lymph nodes.&#xD;
&#xD;
          4. Metastatic melanoma AJCC stage IV, completely resected.&#xD;
&#xD;
          5. Non cutaneous malignant melanoma of respective stages including uveal and mucosal&#xD;
             melanoma.&#xD;
&#xD;
          6. Melanoma can be of either mutant or wild-type B-RAF.&#xD;
&#xD;
          7. Karnofsky performance status over 80 (Normal activity with effort).&#xD;
&#xD;
          8. No active cardio-respiratory disease.&#xD;
&#xD;
          9. Hematocrit over 25% and WBC over 3000.&#xD;
&#xD;
         10. Informed consent of the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Administration of cytotoxic drugs or extensive radiotherapy less than 28 days prior to&#xD;
             protocol administration.&#xD;
&#xD;
          2. Active brain metastases requiring cortico-steroids.&#xD;
&#xD;
          3. Concurrent malignancy (other than skin cancer, carcinoma in situ of cervix and early&#xD;
             stage prostate cancer).&#xD;
&#xD;
          4. Active serious infection.&#xD;
&#xD;
          5. Allergy to penicillin.&#xD;
&#xD;
          6. Patient's wish to withdraw from the study at any stage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2013</study_first_posted>
  <last_update_submitted>May 23, 2013</last_update_submitted>
  <last_update_submitted_qc>May 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>vaccine</keyword>
  <keyword>Resectable AJCC stage IV</keyword>
  <keyword>AJCC stages IIb-c, III</keyword>
  <keyword>Patients with low-burden</keyword>
  <keyword>failed</keyword>
  <keyword>respond</keyword>
  <keyword>one treatment line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

